Compare VanEck Semiconductor ETF (SMH) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Semiconductor ETF vs Tango Therapeutics Inc. — how do they compare? VanEck Semiconductor ETF trades at $554.61 (market cap $71.21B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: VanEck Semiconductor ETF is far larger — about 19× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is more actively traded (9,619,106 versus 7,965,961). Which is the better fit depends on your goals — on Pluang, investors hold VanEck Semiconductor ETF for 102 Days and Tango Therapeutics Inc. for 0 Days on average.
| SMH | TNGX | |
|---|---|---|
Market Cap | $71.21B | $3.75B |
Volume | 7,965,961 | 9,619,106 |
52-Week High | $668.91 | $32.90 |
52-Week Low | $325.10 | $7.50 |
Typical Hold Time | 102 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMH, the VanEck Semiconductor ETF, trades at $564.74, down 4.44% over 24 hours amid sector volatility. Technical indicators show a mixed picture with a bullish overall signal but bearish moving averages, while RSI_6 at 26.18 suggests potential oversold conditions. Recent news highlights strong 2026 performance, with the ETF up around 69% year-to-date, outpacing major holdings like Nvidia, and benefiting from AI-driven semiconductor demand and industry consolidation such as AMD's acquisition of World Labs.
The outlook for SMH remains positive due to robust sector growth and AI expansion, though risks include high concentration in top holdings and sensitivity to tech sector swings. Investors should weigh the ETF's historical outperformance against potential volatility from trade tensions and macroeconomic factors.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
